What is Receptoloc?
Receptoloc is in a group of drugs called histamine-2 blockers. Receptoloc works by decreasing the amount of acid the stomach produces.
Receptoloc is used to treat ulcers in the stomach and intestines. Receptoloc also treats heartburn and erosive esophagitis caused by gastroesophageal reflux disease (GERD), a condition in which acid backs up from the stomach into the esophagus.
Receptoloc may also be used for purposes not listed in this medication guide.
Receptoloc indications
Receptoloc
Oral Solution is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks.
Receptoloc
Oral Solution is indicated for maintenance therapy for duodenal ulcer patients at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with Receptoloc for longer than 1 year are not known.
Receptoloc
Oral Solution is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD.
Receptoloc
Oral Solution is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration.
In pediatric patients, Receptoloc
Oral Solution is indicated for ages 12 years and older. Receptoloc
Oral Solution is indicated for up to 8 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD.
How should I use Receptoloc?
Use Receptoloc solution as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Receptoloc solution maybe taken with or without food.
- Use a measuring device marked for medicine dosing. Ask your health care provider or pharmacist if you are unsure of how to measure the dose.
- Continue to use Receptoloc solution even if you feel well. Do not miss any doses.
- Antacids may be taken as needed to help relieve stomach pain, unless your health care provider instructed otherwise.
- If you miss a dose of Receptoloc solution, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Receptoloc solution.
Uses of Receptoloc in details
Use: Labeled Indications
Duodenal ulcer: Treatment of active duodenal ulcer for up to 8 weeks and maintenance therapy after healing of active ulcer in adults.
Gastric ulcer, benign: Treatment of active benign gastric ulcer for up to 8 weeks in adults.
Gastroesophageal reflux disease: Treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to gastroesophageal reflux disease (GERD) for up to 12 weeks in adults (capsules and oral solution) and up to 8 weeks in children 12 years and older (oral solution only).
Off Label Uses
Helicobacter pylori eradication (component of a multidrug regimen)
Data from two randomized, controlled, open-label studies support the use of Receptoloc, as part of triple therapy with amoxicillin and clarithromycin, for eradication of Helicobacter pylori in patients with active peptic ulcers and evidence of H. pylori infection. Additional trials may be necessary to further define the role of Receptoloc in this condition.
Based on the American College of Gastroenterology Guideline on the Management of Helicobacter pylori Infection, an H-receptor antagonist is recommended in sepsis or septic shock patients who have GI bleeding risk factors.
Receptoloc description
A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202)
Receptoloc dosage
Axid
Oral Solution Dosage
Generic name: Receptoloc 15mg in 1mL
Dosage form: oral solution
See also:
- Axid capsule
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Active Duodenal Ulcer —The recommended oral dosage for adults is 300 mg once daily at bedtime. An alternative dosage regimen is 150 mg twice daily.
Maintenance of Healed Duodenal Ulcer —The recommended oral dosage for adults is 150 mg once daily at bedtime.
Gastroesophageal Reflux Disease —The recommended oral dosage in adults for the treatment of erosions, ulcerations, and associated heartburn is 150 mg twice daily.
Active Benign Gastric Ulcer—The recommended oral dosage is 300 mg given either as 150 mg twice daily or 300 mg once daily at bedtime. Prior to treatment, care should be taken to exclude the possibility of malignant gastric ulceration.
Each mL of Axid
Oral Solution contains 15 mg of Receptoloc. In adults, Axid
Oral Solution may be substituted for any of the above indications using equivalent doses of the oral solution.
Pediatric Dosing—Each mL of oral solution contains 15 mg of Receptoloc. Axid
Oral Solution is indicated for pediatric patients 12 years of age or older. For pediatric patients 12 years of age and older, the dosage of Receptoloc is 150 mg b.i.d. (2 tsp, b.i.d.)
The following dosage recommendations are provided:
Erosive Esophagitis—For pediatric patients 12 years or older, the dosage is 150 mg b.i.d. (300 mg/d). The maximum daily dose for Receptoloc PO is 300 mg/d. The dosing duration may be up to eight weeks.
Gastroesophageal Reflux Disease—For pediatric patients 12 years or older, the dosage is 150 mg b.i.d. (300 mg/d). The maximum daily dose for Receptoloc PO is 300 mg/d. The dosing duration may be up to eight weeks.
Dosage Adjustment for Patients With Moderate to Severe Renal Insufficiency —The dose for patients with renal dysfunction should be reduced as follows:
| Active Duodenal Ulcer, GERD, and Benign Gastric Ulcer | |
| Creatine Clearance | Dose |
| 20-50 mL/min | 150 mg daily |
| <20 mL/min | 150 mg every other day |
| Maintenance Therapy | |
| Creatine Clearance | Dose |
| 20-50 mL/min | 150 mg every other day |
| <20 mL/min | 150 mg every 3 days |
Some elderly patients may have creatinine clearances of less than 50 mL/min, and, based on pharmacokinetic data in patients with renal impairment, the dose for such patients should be reduced accordingly. The clinical effects of this dosage reduction in patients with renal failure have not been evaluated.
Based on the pharmacokinetic data in elderly patients with renal impairment, pediatric patients with creatinine clearances less than 50 mL/min should have their dose of Receptoloc reduced accordingly. The clinical effects of this dose reduction in pediatric patients with renal failure have not been evaluated.
More about Axid
Oral Solution (Receptoloc)
- Side Effects
- During Pregnancy or Breastfeeding
- Dosage Information
- Drug Interactions
- 0 Reviews · Be the first to review/rate this drug
Consumer resources
- Other brands: Axid, Axid Pulvules
Professional resources
- Axid
Oral Solution (FDA)
- Receptoloc (AHFS Monograph)
Other formulations
- Receptoloc
Receptoloc interactions
See also:
What other drugs will affect Receptoloc?
No interactions have been observed between Receptoloc and theophylline, chlordiazepoxide, lorazepam, lidocaine, phenytoin, and warfarin. Receptoloc [Usan:Ban:Inn:Jan] does not inhibit the cytochrome P-450-linked drug-metabolizing enzyme system; therefore, drug interactions mediated by inhibition of hepatic metabolism are not expected to occur. In patients given very high doses (3900 mg) of aspirin daily, increases in serum salicylate levels were seen when Receptoloc, 150 mg b.i.d., was administered concurrently.
Receptoloc side effects
See also:
What are the possible side effects of Receptoloc?
Worldwide, controlled clinical trials of Receptoloc included over 6,000 patients given Receptoloc in studies of varying durations. Placebo-controlled trials in the United States and Canada included over 2,600 patients given Receptoloc and over 1,700 given placebo. Among the adverse events in these placebo-controlled trials, anemia (0.2% vs 0%) and urticaria (0.5% vs 0.1%) were significantly more common in the Receptoloc group.
Incidence in Placebo-Controlled Clinical Trials in the United States and Canada—Table 7 lists adverse events that occurred at a frequency of 1% or more among Receptoloc-treated patients who participated in placebo-controlled trials. The cited figures provide some basis for estimating the relative contribution of drug and non-drug factors to the side-effect incidence rate in the population studied.
| *Events reported by at least 1% of Receptoloc-treated patients are included. | |||||
| Percentage of Patients Reporting Event | Percentage of Patients Reporting Event | ||||
| Body System/ Adverse Event* | Receptoloc (N=2,694) | Placebo (N=1,729) | Body System/ Adverse Event* | Receptoloc (N=2,694) | Placebo (N=1,729) |
| Body as a Whole | Nervous | ||||
| Headache | 16.6 | 15.6 | Dizziness | 4.6 | 3.8 |
| Pain | 4.2 | 3.8 | Insomnia | 2.7 | 3.4 |
| Asthenia | 3.1 | 2.9 | Abnormal dreams | 1.9 | 1.9 |
| Chest pain | 2.3 | 2.1 | Somnolence | 1.9 | 1.6 |
| Infection | 1.7 | 1.1 | Anxiety | 1.8 | 1.4 |
| Injury, accident | 1.2 | 0.9 | Nervousness | 1.1 | 0.8 |
| Digestive | Respiratory | ||||
| Diarrhea | 7.2 | 6.9 | Rhinitis | 9.8 | 9.6 |
| Dry mouth | 1.4 | 1.3 | Pharyngitis | 3.3 | 3.1 |
| Tooth disorder | 1.0 | 0.8 | Sinusitis | 2.4 | 2.1 |
| Musculoskeletal | Cough, increased | 2.0 | 2.0 | ||
| Myalgia | 1.7 | 1.5 | Skin and Appendages | ||
| Rash | 1.9 | 2.1 | |||
| Pruritis | 1.7 | 1.3 | |||
| Special Senses | |||||
| Amblyopia | 1.0 | 0.9 | |||
A variety of less common events were also reported; it was not possible to determine whether these were caused by Receptoloc.
Hepatic—Hepatocellular injury, evidenced by elevated liver enzyme tests (SGOT [AST], SGPT [ALT], or alkaline phosphatase), occurred in some patients and was possibly or probably related to Receptoloc. In some cases, there was marked elevation of SGOT, SGPT enzymes (greater than 500 IU/L) and, in a single instance, SGPT was greater than 2,000 IU/L. The overall rate of occurrences of elevated liver enzymes and elevations to 3 times the upper limit of normal, however, did not significantly differ from the rate of liver enzyme abnormalities in placebo-treated patients. All abnormalities were reversible after discontinuation of Receptoloc. Since market introduction, hepatitis and jaundice have been reported. Rare cases of cholestatic or mixed hepatocellular and cholestatic injury with jaundice have been reported with reversal of the abnormalities after discontinuation of Receptoloc.
Cardiovascular—In clinical pharmacology studies, short episodes of asymptomatic ventricular tachycardia occurred in 2 individuals administered Receptoloc and in 3 untreated subjects.
CNS—Rare cases of reversible mental confusion have been reported.
Endocrine—Clinical pharmacology studies and controlled clinical trials showed no evidence of antiandrogenic activity due to Receptoloc. Impotence and decreased libido were reported with similar frequency by patients who received Receptoloc and by those given placebo. Rare reports of gynecomastia occurred.
Hematologic—Anemia was reported significantly more frequently in Receptoloc- than in placebo-treated patients. Fatal thrombocytopenia was reported in a patient who was
treated with Receptoloc and another H2-receptor antagonist. On previous occasions, this
patient had experienced thrombocytopenia while taking other drugs. Rare cases of thrombocytopenic purpura have been reported.
Integumental — Sweating and urticaria were reported significantly more frequently in Receptoloc- than in placebo-treated patients. Rash and exfoliative dermatitis were also reported. Vasculitis has been reported rarely.
Hypersensitivity — As with other H2-receptor antagonists, rare cases of anaphylaxis following administration of Receptoloc have been reported. Rare episodes of hypersensitivity reactions (eg, bronchospasm, laryngeal edema, rash, and eosinophilia) have been reported.
Body as a Whole—Serum sickness-like reactions have occurred rarely in conjunction with Receptoloc use.
Genitourinary—Reports of impotence have occurred.
Other—Hyperuricemia unassociated with gout or nephrolithiasis was reported. Eosinophilia, fever, and nausea related to Receptoloc administration have been reported.
Postmarketing
Respiratory—pneumonia
Adverse Reactions (Pediatric)
In controlled clinical trials in pediatric patients (age 2 to 18 years), Receptoloc was found to be generally safe and well tolerated. The principal adverse experiences (> 5%) were pyrexia, nasopharyngitis, diarrhea, vomiting, irritability, nasal congestion and cough. Most adverse events were mild or moderate in severity. Mild elevations in serum transaminase (1-2 x ULN) were noted in some patients. One subject experienced a seizure by EEG diagnosis after taking Axid
Oral Solution 2.5 mg/kg b.i.d. for 23 days. The adverse reactions reported for Receptoloc may also occur with Axid
Oral Solution.
Receptoloc contraindications
See also:
What is the most important information I should know about Receptoloc?
You should not use this medication if you are allergic to Receptoloc or similar medications such as ranitidine (Zantac), cimetidine (Tagamet), or famotidine (Pepcid).
Before taking Receptoloc, tell your doctor if you have kidney or liver disease, or stomach cancer or other problems.
Avoid taking cimetidine (Tagamet), ranitidine (Zantac), or famotidine (Pepcid) while you are taking Receptoloc, unless your doctor has told you to.
Receptoloc may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert.
Receptoloc may be only part of a complete program of treatment that also includes changes in diet or lifestyle habits. Follow your doctor's instructions very closely.
Heartburn is often confused with the first symptoms of a heart attack. Seek emergency medical attention if you have chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, and a general ill feeling.
Active ingredient matches for Receptoloc:
Nizatidine in Egypt.
List of Receptoloc substitutes (brand and generic names) | Sort by popularity |
| Unit description / dosage (Manufacturer) | Price, USD |
| Nizaxid (Chile, France, Portugal, South Korea) | |
| Capsule; Oral; Nizatidine 300 mg (Norgine) | |
| Nizotin (Romania) | |
| Nolcer (Philippines) | |
| Nolcer 150 mg x 100's (Suzikem Drugs Pvt. Ltd.) | $ 0.75 |
| Nolcer 25 mg/1 mL x 4 mL (Suzikem Drugs Pvt. Ltd.) | $ 2.49 |
| Nolcer 20 mg Capsule (Suzikem Drugs Pvt. Ltd.) | $ 0.05 |
| NOLCER cap 0 20 mg x 10's (Suzikem Drugs Pvt. Ltd.) | $ 0.06 |
| Novo-Nizatidine (Canada) | |
| Capsule; Oral; Nizatidine 150 mg | |
| Capsule; Oral; Nizatidine 300 mg | |
| Novo-nizatidine capsule 300 mg (Novopharm Limited (Canada)) | |
| Novo-nizatidine capsule 150 mg (Novopharm Limited (Canada)) | |
| Nyzant (Turkey) | |
| Ozeltan (Greece) | |
| Panaxid (Luxembourg) | |
| PHL-Nizatidine | |
| Capsule; Oral; Nizatidine 150 mg | |
| Capsule; Oral; Nizatidine 300 mg | |
| PHL-nizatidine capsule 150 mg (Pharmel Inc (Canada)) | |
| PHL-nizatidine capsule 300 mg (Pharmel Inc (Canada)) | |
| PMS-Nizatidine (Canada) | |
| Capsule; Oral; Nizatidine 150 mg | |
| Capsule; Oral; Nizatidine 300 mg | |
| PMS-nizatidine capsule 300 mg (Pharmascience Inc (Canada)) | |
| Prospaxid (Portugal) | |
| Sai Fa Lei (China) | |
| Tacidine (Australia) | |
| Capsule; Oral; Nizatidine 150 mg (Alphapharm) | |
| Capsule; Oral; Nizatidine 300 mg (Alphapharm) | |
| Tazac (Australia, Taiwan) | |
| Capsule; Oral; Nizatidine 150 mg (Eli Lilly) | |
| Capsule; Oral; Nizatidine 300 mg (Eli Lilly) | |
| Tazac 150 mg x 30's (Eli Lilly) | |
| Tizanon (Japan) | |
| Ulcfree (Egypt) | |
| Ulcogastrin (Greece) | |
| Ulcosal (Spain) | |
| Ulcosol | |
| Uldadin (Mexico) | |
| Ultara (Vietnam) | |
| Ultara 150 mg x 3 Blister x 10 Tablet | |
| Ultara 150 mg x 6 Blister x 10 Tablet | |
| Ulxid | |
| Ulxit (Austria) | |
| Vaxidin (Vietnam) | |
| Vaxidin 150 mg x 3 Blister x 10 Tablet | |
| Zanizal (Italy) | |
| Zastidin (Vietnam) | |
| Zastidin 150 mg x 3 Blister x 10 Tablet | |
| Zastidine (South Korea) | |
See 148 substitutes for Receptoloc | |
References
- DailyMed. "NIZATIDINE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "nizatidine". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
- DrugBank. "nizatidine". http://www.drugbank.ca/drugs/DB00585 (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Receptoloc are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Receptoloc. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported useful
No survey data has been collected yetConsumer reported price estimates
No survey data has been collected yetConsumer reported time for results
No survey data has been collected yetConsumer reported age
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
